BioInvent International AB: Year-end report January 1 – December 31, 2025

Summary by AI BETAClose X

BioInvent reported strategic portfolio changes in 2025 to accelerate lead programs BI-1808 and BI-1206, presenting promising Phase 2a data for BI-1808 in T-cell lymphoma and BI-1206 in non-Hodgkin's Lymphoma, alongside new trials and Orphan Drug Designations. Financials for Q4 2025 showed net sales of SEK 3.0 million and a loss after tax of SEK -125.8 million, while full-year 2025 net sales reached SEK 226.5 million with a loss after tax of SEK -332.9 million, and liquid funds stood at SEK 592.7 million as of December 31, 2025.

Disclaimer*

UK 100

Latest directors dealings